Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cleve Clin J Med. 2001 Nov;68(11):945-51.

Role of alendronate and risedronate in preventing and treating osteoporosis.

Author information

  • 1Department of Pharmacy, The Cleveland Clinic Foundation, OH 44195, USA.

Abstract

Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy. Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form. On the other hand, alendronate is not approved for preventing glucocorticoid-induced osteoporosis, whereas risedronate carries this indication.

PMID:
11718433
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk